<div xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="" dtd-version="1.3" language="en" class="article" sectionnumbered="no" referencenumbered="yes" mathml="yes">
   <div class="front">
      <div class="journal-meta">
         <journal-id journal-id-type="nlm-ta">Neonatal Network</journal-id>
         <journal-id journal-id-type="publisher">NN</journal-id>
         <div class="journal-title-group">
            <div class="journal-title">Neonatal Network</div>
            <div abbrev-type="publisher" class="abbrev-journal-title">NN</div>
         </div>
         <issn pub-type="ppub">0730-0832 </issn>
         <issn pub-type="epub">1539-2880</issn>
         <publisher>
            <publisher-name>Neonatal Network</publisher-name>
         </publisher>
      </div>
      <div class="article-meta">
         <article-id pub-id-type="publisher-id" fm-preference="1">NN-2021-0011</article-id>
         <article-id pub-id-type="doi" fm-preference="1">10.1891/NN.2021-0011</article-id>
         <article-categories fm-preference="3">
            <subj-group subj-group-type="heading">
               <subject>Research</subject>
            </subj-group>
         </article-categories>
         <div class="title-group" fm-preference="4">
            <div class="article-title">Tumor dormancy at bedside: a late awakening</div>
         </div>
         <div class="contrib-group" fm-preference="5">
            <contrib contrib-type="author" rid="aff1" id="Au1">
               <string-name>
                  <given-names>Veera</given-names>
                  <surname>Bala</surname>
               </string-name>
            </contrib>
            <contrib contrib-type="author" rid="aff2" id="Au2">
               <string-name>
                  <given-names>Vaigundam</given-names>
                  <surname>SRi</surname>
               </string-name>
            </contrib>
            <contrib contrib-type="author" rid="aff2" id="Au3">
               <string-name>
                  <given-names>Venkat</given-names>
                  <surname>Ravi</surname>
               </string-name>
               <email>VenkataR001@reedelsevier.com</email>
            </contrib>
            <contrib contrib-type="author" rid="aff1" id="Au4" corresp="yes" orcid="http://orcid.org/">
               <string-name>
                  <given-names>Bob</given-names>
                  <surname>Donald</surname>
               </string-name>
            </contrib>
         </div>
         <div class="affiliation-group" fm-preference="6">
            <aff id="aff1">
               <institution>Unit of Medical Statistics</institution>
               <institution>Biometry and Bioinformatics "Giulio A. Maccacaro"</institution>
               <institution>Department of Clinical Sciences and Community Health</institution>
               <institution>University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori</institution>
               <city>Milan</city>
               <country>Italy.</country>
            </aff>
            <aff id="aff2">
               <institution>Breast Cancer Translational Research Laboratory</institution>
               <institution>Université Libre de Bruxelles</institution>
               <institution>Institut Jules Bordet</institution>
               <postal-code>1000</postal-code>
               <city>Brussels</city>
               <country>Belgium</country>
            </aff>
         </div>
         <div class="author-notes" fm-preference="7">
            <div class="fn">
               <div class="Para" id="Par1"><i><b>Funding:</b>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</i></div>
            </div>
            <div id="a_cor1" specific-use="meta" class="corresp">
               Correspondence: Gabrielle Deschamps, Email: 
               <email>gdeschamps@regis.edu</email>
               <span class="EditNotAllowedNoToolTip oxe_aq_div oxe_aq" type="coast" id="9698473E7_57587784E8" title="unidentified style found. Could you please check?">AQ</span>
            </div>
         </div>
         <pub-date pub-type="epub" fm-preference="8">
            <day>01</day>
            <month>February</month>
            <year>2022</year>
         </pub-date>
         <volume fm-preference="9">41</volume>
         <issue fm-preference="12">3</issue>
         <elocation-id fm-preference="13">NN.2021-0011</elocation-id>
         <history fm-preference="23">
            <date date-type="received">
               <day>26</day>
               <month>07</month>
               <year>2021</year>
            </date>
            <date date-type="accepted">
               <day>09</day>
               <month>08</month>
               <year>2021</year>
            </date>
         </history>
         <permissions fm-preference="25">
            <copyright-year>2022</copyright-year>
         </permissions>
         <div id="ABS1" class="abstract" fm-preference="28" type="abstract">
            <div class="Para" id="Par2">Breast cancer recurrence may occur at variable times following primary tumor removal. The corresponding event dynamics displays a structured multipeak pattern, which can be explained by the occurrence of microscopic phases of metastasis quiescence (tumor dormancy) followed by wake up, growth and timed clinical appearance. This model provides a meaningful justification of the early recurrence pattern and even explains the effectiveness of adjuvant systemic therapies. Yet, late recurrences, which were less investigated, are fairly little known and a few researchers support<strike>ed</strike> their steady state appearance. We report here the analysis of the late clinical course from patients who were disease-free at 5 years of follow-up, which again displays a structured pattern, supporting the view that tumor dormancy can explain the late recurrence risk as well. Tailored treatments are needed to address late clinical recurrences.</div>
         </div>
         <div id="kwdGroup" class="kwd-group" fm-preference="30">
            <div class="title">Keywords</div>
            <div id="kwd1" class="kwd">breast cancer</div>
            <div id="kwd2" class="kwd">tumor dormancy</div>
            <div id="kwd3" class="kwd">tumor homeostasis</div>
            <div id="kwd4" class="kwd">recurrence dynamics</div>
            <div id="kwd5" class="kwd">late recurrences</div>
         </div>
         <counts fm-preference="34">
            <page-count count="0"> </page-count>
         </counts>
      </div>
      <div preference="35" class="RawAuthorGroup">
         <div class="Para" id="Par1">Tumor dormancy at bedside: a late awakening</div>
         <div class="Para" id="Par2">Veera Bala1, Vaigundam SRi2, Venkat Ravi2, Bob Donald1,*</div>
         <div class="Para" id="Par3">1 Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.</div>
         <div class="Para" id="Par4">2 Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium</div>
         <div class="Para" id="Par5">*Corresponding author. VenkataR001@reedelsevier.com</div>
         <div class="Para" id="Par6">Abstract:</div>
         <div class="Para" id="Par7">Breast cancer recurrence may occur at variable times following primary tumor removal. The corresponding event dynamics displays a structured multipeak pattern, which can be explained by the occurrence of microscopic phases of metastasis quiescence (tumor dormancy) followed by wake up, growth and timed clinical appearance. This model provides a meaningful justification of the early recurrence pattern and even explains the effectiveness of adjuvant systemic therapies. Yet, late recurrences, which were less investigated, are fairly little known and a few researchers supported their steady state appearance. We report here the analysis of the late clinical course from patients who were disease-free at 5 years of follow-up, which again displays a structured pattern, supporting the view that tumor dormancy can explain the late recurrence risk as well. Tailored treatments are needed to address late clinical recurrences.</div>
         <div class="Para" id="Par8">Keywords</div>
         <div class="Para" id="Par9">breast cancer; tumor dormancy; tumor homeostasis; recurrence dynamics; late recurrences</div>
      </div>
   </div>

</div>